Kane Biotech Inc. (KNE.V)

CAD 0.1

(0.0%)

Total Debt Summary of Kane Biotech Inc.

  • Kane Biotech Inc.'s latest annual total debt in 2023 was 8.27 Million CAD , up 35.04% from previous year.
  • Kane Biotech Inc.'s latest quarterly total debt in 2024 Q2 was 2.38 Million CAD , down -74.05% from previous quarter.
  • Kane Biotech Inc. reported annual total debt of 6.85 Million CAD in 2022, up 45.43% from previous year.
  • Kane Biotech Inc. reported annual total debt of 4.71 Million CAD in 2021, up 109.56% from previous year.
  • Kane Biotech Inc. reported quarterly total debt of 2.38 Million CAD for 2024 Q2, down -74.05% from previous quarter.
  • Kane Biotech Inc. reported quarterly total debt of 8.27 Million CAD for 2023 Q4, down -9.97% from previous quarter.

Annual Total Debt Chart of Kane Biotech Inc. (2023 - 2003)

Historical Annual Total Debt of Kane Biotech Inc. (2023 - 2003)

Year Total Debt Total Debt Growth
2023 8.27 Million CAD 35.04%
2022 6.85 Million CAD 45.43%
2021 4.71 Million CAD 109.56%
2020 2.24 Million CAD 1224.93%
2019 169.81 Thousand CAD -66.04%
2018 500 Thousand CAD 0.0%
2017 - CAD -100.0%
2016 479.99 Thousand CAD 9.43%
2015 438.64 Thousand CAD -2.2%
2014 448.5 Thousand CAD 8.53%
2013 413.24 Thousand CAD 0.0%
2012 - CAD 0.0%
2011 - CAD 0.0%
2010 - CAD 0.0%
2009 - CAD 0.0%
2008 - CAD 0.0%
2007 - CAD 0.0%
2006 - CAD 0.0%
2005 - CAD 0.0%
2004 - CAD 0.0%
2003 - CAD 0.0%

Peer Total Debt Comparison of Kane Biotech Inc.

Name Total Debt Total Debt Difference
Arch Biopartners Inc. 5.01 Million CAD -64.985%
Covalon Technologies Ltd. 1.56 Million CAD -429.674%
Hemostemix Inc. 4.32 Million CAD -91.507%
Universal Ibogaine Inc. 1.73 Million CAD -376.267%
MedMira Inc. 9.27 Million CAD 10.735%
Marvel Biosciences Corp. 1 Million CAD -727.597%
NervGen Pharma Corp. 197.19 Thousand CAD -4096.953%
XORTX Therapeutics Inc. 15.17 Thousand CAD -54429.69%